Seminars in Thoracic and Cardiovascular Surgery
Volume 19, Issue 3 , Pages 217-224 , Autumn 2007

Integration of Mediastinal Staging Techniques for Lung Cancer

  • Frank C. Detterbeck, MD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Frank C. Detterbeck, MD, Division of Thoracic Surgery, Department of Surgery, Yale University, 330 Cedar St, FMB 128, New Haven, CT 06520-8062.

References 

  1. Detterbeck FC, Jantz M, Wallace M, et al: Invasive Mediastinal Staging of Lung Cancer: An ACCP Evidence Based Clinical Practice Guideline (ed 2). Chest 2007 (in press)
  2. Detterbeck FC, Jones DR, Parker LA. Intrathoracic staging. In:  Detterbeck FC,  Rivera M,  Socinski M, et al. editor. Diagnosis and Treatment of Lung Cancer: An Evidence-Based Guide for the Practicing Clinician. Philadelphia: W.B. Saunders; 2001;p. 73–93
  3. Dietlein M, Weber K, Gandjour A, et al. Cost-effectiveness of FDG-PET for the management of potentially operable non-small cell lung cancer; priority for a PET-based strategy after nodal-negative CT results. Eur J Nucl Med. 2000;27:1598–1609
  4. Gould MK, Kuschner W, Rydzak C, et al. Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer: a meta-analysis. Ann Intern Med. 2003;139:879–892
  5. Serra M, Cicera L, Rami-Porta R, et al. Routine positron tomography (PET) and selective mediastinoscopy is as good as routine mediastinoscopy to rule out N2 disease in non-small cell lung cancer (NSCLC). J Clin Oncol. 2006;24(suppl):371s
  6. Cerfolio RJ, Bryant A, Ojha B, et al. Improving the inaccuracies of clinical staging of patients with NSCLC: a prospective trial. Ann Thorac Surg. 2005;80:1207–1214
  7. Watanabe Y, Hayashi Y, Shimizu J, et al. Mediastinal nodal involvement and the prognosis of non-small cell lung cancer. Chest. 1991;100:422–428
  8. Cybulsky IJ, Lanza LA, Ryan MB, et al. Prognostic significance of computed tomography in resected N2 lung cancer. Ann Thorac Surg. 1992;54:533–537
  9. Ichinose Y, Kato H, Koike T, et al. Overall survival and local recurrence of 406 completely resected stage IIIa-N2 non-small cell lung cancer patients: questionnaire survey of the Japan Clinical Oncology Group to plan for clinical trials. Lung Cancer. 2001;34:29–36
  10. Detterbeck F: What to do with surprise N2. J Thorac Oncol 2007 (in press)
  11. Detterbeck FC, DeCamp M, Kohman L, et al. Invasive staging: the guidelines. Chest. 2003;123:167S–175S
  12. Detterbeck FC, Socinski MA. Induction therapy and surgery for I-IIIa, b non-small cell lung cancer. In:  Detterbeck FC, et al. editor. Diagnosis and Treatment of Lung Cancer: An Evidence-Based Guide for the Practicing Clinician. Philadelphia: W. B. Saunders; 2001;p. 257–266
  13. Betticher DC, Hsu Schmitz SF, Totsch M, et al. Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial. J Clin Oncol. 2003;21:1752–1759
  14. Detterbeck FC, Falen S, Rivera MP, et al. Seeking a home for a PET, part 2: defining the appropriate place for positron emission tomography imaging in the staging of patients with suspected lung cancer. Chest. 2004;125:2300–2308
  15. Akhurst T, Downey R, Ginsberg M, et al. An initial experience with FDG-PET in the imaging of residual disease after induction therapy for lung cancer. Ann Thorac Surg. 2002;72:259–266
  16. De Waele M, Hendriks J, Lauwers P, et al. Nodal status at repeat mediastinoscopy determines survival in non-small cell lung cancer with mediastinal nodal involvement, treated by induction therapy. Eur J Cardio-Thorac Surg. 2006;29:240–243
  17. De Leyn P, Stroobants S, De Wever W, et al. Prospective comparative study of integrated positron emission tomography-computed tomography scan compared with remediastinoscopy in the assessment of residual mediastinal lymph node disease after induction chemotherapy for mediastinoscopy-proven stage IIIA-N2 non–small-cell lung cancer: a Leuven Lung Cancer Group Study. J Clin Oncol. 2006;24:3333–3339
  18. Cerfolio RJ, Bryant A, Winokur T, et al. Repeat FDG-PET after neoadjuvant therapy is a predictor of pathologic response in patients with non-small cell lung cancer. Ann Thorac Surg. 2004;78:1903–1909discussion 1909
  19. Cerfolio RJ, Bryant AS, Ojha B. Restaging patients with N2 (stage IIIa) non-small cell lung cancer after neoadjuvant chemoradiotherapy: a prospective study. Thorac Cardiovasc Surg. 2006;131:1229–1235
  20. Lardinois D, Schallberger A, Betticher D, et al. Postinduction video-mediastinoscopy is as accurate and safe as video-mediastinoscopy in patients without pretreatment for potentially operable non-small cell lung cancer. Ann Thorac Surg. 2003;75:1102–1106
  21. Verhagen AFT, Bootsma G, Tjan-Heijnen V, et al. FDG-PET in staging lung cancer: how does it change the algorithm?. Lung Cancer. 2004;44:175–181
  22. Pozo-Rodríguez F, Martín de Nicolás JL, Sánchez-Nistal MA, et al. Accuracy of helical computed tomography and [18F] fluorodeoxyglucose positron emission tomography for identifying lymph node mediastinal metastases in potentially resectable non-small-cell lung cancer. J Clin Oncol. 2005;23:8348–8356
  23. Cerfolio RJ, Bryant AS, Eloubeidi MA. Routine mediastinoscopy and esophageal ultrasound fine-needle aspiration in patients with non-small cell lung cancer who are clinically N2 negative: a prospective study. Chest. 2006;130:1791–1795
  24. Pearson FG, DeLarue N, Ilves R, et al. Significance of positive superior mediastinal nodes identified at mediastinoscopy in patients with resectable cancer of the lung. J Thorac Cardiovasc Surg. 1982;83:1–11
  25. Vansteenkiste JF, DeLeyn P, Deneffe G, et al. Survival and prognostic factors in resected N2 non-small cell lung cancer: a study of 140 cases. Ann Thorac Surg. 1997;63:1441–1450
  26. Coughlin M, Deslauriers J, Beaulieu M, et al. Role of mediastinoscopy in pretreatment staging of patients with primary lung cancer. Ann Thorac Surg. 1985;40:556–560
  27. Goldstraw P, Mannam G, Kaplan D, et al. Surgical management of non-small-cell lung cancer with ipsilateral mediastinal node metastasis (N2 disease). J Thorac Cardiovasc Surg. 1994;107:19–28
  28. Daly BDT, Mueller J, Faling L, et al. N2 lung cancer: outcome in patients with false-negative computed tomographic scans of the chest. J Thorac Cardiovasc Surg. 1993;105:904–911
  29. MacManus MP, Hicks R, Matthews J, et al. High rate of detection of unsuspected distant metastases by PET in apparent stage III non-small-cell lung cancer: Implications for radical radiation therapy. Int J Radiation Oncology Biol Phys. 2001;50:287–293
  30. Reed C, Harpole DH, Posther KE, et al. Results of the American College of Surgeons Oncology Group Z0050 Trial: the utility of positron emission tomography in staging potentially operable non-small cell lung cancer. J Thorac Cardiovasc Surg. 2003;126:1943–1951
  31. Weder W, Schmid RA, Bruchhaus H, et al. Detection of extrathoracic metastases by positron emission tomography in lung cancer. Ann Thorac Surg. 1998;66:886–893
  32. Viney RC, Boyer MJ, King MT, et al. Randomized controlled trial of the role of positron emission tomography in the management of stage I and II non-small-cell lung cancer. J Clin Oncol. 2004;22:2357–2362
  33. Farrell MA, McAdams HP, Herndon JE, et al. Non-small cell lung cancer: FDG PET for nodal staging in patients with stage I disease. Radiology. 2000;215:886–890
  34. Silvestri G, Gould M, Margolis M, et al: Non-invasive staging of non-small cell lung cancer: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest 2007 (in press)
  35. Meyers BF, Haddad F, Siegel B, et al. Cost-effectiveness of routine mediastinoscopy in computed tomography- and positron emission tomography-screened patients with stage I lung cancer. J Thorac Cardiovasc Surg. 2006;131:822–829
  36. Smythe WR. Treatment of stage I non-small cell lung carcinoma. Chest. 2003;123(suppl):181S–187S
  37. Lardinois D, De Leyn P, Van Schil P, et al. ESTS guidelines for intraoperative lymph node staging in non-small cell lung cancer. Eur J Cardio-Thorac Surg. 2006;30:787–792
  38. Bollen ECM, van Duin CJ, Theunissen P, et al. Mediastinal lymph node dissection in resected lung cancer: morbidity and accuracy of staging. Ann Thorac Surg. 1993;55:961–966
  39. Gaer JAR, Goldstraw P. Intraoperative assessment of nodal staging at thoracotomy for carcinoma of the bronchus. Eur J Cardio-Thorac Surg. 1990;4:207–210
  40. Wu Y, Huang ZF, Wang SY, et al. A randomized trial of systematic nodal dissection in resectable non-small cell lung cancer. Lung Cancer. 2002;36:1–6
  41. Izbicki JR, Passlick B, Karg O, et al. Impact on radical systematic mediastinal lymphadenectomy on tumor staging in lung cancer. Ann Thorac Surg. 1995;59:209–214
  42. Allen MS, Darling G, Pechet T, et al. Morbidity and mortality of major pulmonary resections in patients with early-stage lung cancer: initial results of the randomized, prospective ACOSOG Z0030 Trial. Ann Thorac Surg. 2006;81:1013–1020
  43. Keller SM, Adak S, Wagner H, et al. Mediastinal lymph node dissection improves survival in patients with stages II and IIIa non-small cell lung cancer; from the Eastern Cooperative Oncology Group. Ann Thorac Surg. 2000;70:358–365
  44. Sugi K, Nawata K, Fujita N, et al. Systematic lymph node dissection for clinically diagnosed peripheral non-small-cell lung cancer less than 2 cm in diameter. World J Surg. 1998;22:290–294
  45. Izbicki JR, Thetter O, Habekost M, et al. Radical systematic mediastinal lymphadenectomy in non-small cell lung cancer: a randomized controlled trial. Br J Surg. 1994;81:229–235
  46. Funatsu T, Matsubara Y, Ikeda S, et al. Preoperative mediastinoscopic assessment of N factors and the need for mediastinal lymph node dissection in T1 lung cancer. J Thorac Cardiovasc Surg. 1994;108:321–328
  47. Martini N, Flehinger BJ, Zaman MB, et al. Results of resection in non-oat cell carcinoma of the lung with mediastinal lymph node metastases. Ann Surg. 1983;198:386–397
  48. Mountain CF. Surgery for Stage IIIa-N2 non-small cell lung cancer. Cancer. 1994;73:2589–2598
  49. Andre F, Grunenwald D, Pignon JP, et al. Survival of patients with resected N2 non-small-cell lung cancer: Evidence for a subclassification and implications. J Clin Oncol. 2000;18:2981–2989
  50. Vansteenkiste JF, De Leyn P, Deneffe G, et al. Clinical prognostic factors in surgically treated stage IIIA-N2 non-small cell lung cancer: analysis of the literature. Lung Cancer. 1998;19:3–13
  51. Detterbeck FC, Jones DR. Surgical treatment of stage IIIa (N2) non-small cell lung cancer. In:  Detterbeck FC,  Rivera M,  Socinski M, et al. editor. Diagnosis and Treatment of Lung Cancer: An Evidence-Based Guide for the Practicing Clinician. Philadelphia: W.B. Saunders; 2001;p. 244–256
  52. Patterson GA, Piazza D, Pearson FG, et al. Significance of metastatic disease in subaortic lymph nodes. Ann Thorac Surg. 1987;43:155–159
  53. Sakao Y, Miyamoto H, Yamazaki A, et al. The spread of metastatic lymph nodes to the mediastinum from left upper lobe cancer: results of superior mediastinal nodal dissection through a median sternotomy. Eur J Cardiothorac Surg. 2006;30:543–547
  54. Okada M, Tsubota N, Yoshimura M, et al. Prognosis of completely resected pN2 non-small cell lung carcinomas: what is the significant node that affects survival?. J Thorac Cardiovasc Surg. 1999;118:270–275

PII: S1043-0679(07)00101-3

doi: 10.1053/j.semtcvs.2007.07.011

Seminars in Thoracic and Cardiovascular Surgery
Volume 19, Issue 3 , Pages 217-224 , Autumn 2007

Article Tools

* Image Usage & Resolution